Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK119 + AK112 in advanced solid tumors
CTR20230347Phase 2Active
- Sponsor
- Akeso, Inc.
- Start
- Apr 2023
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of ambuzutinib, ivonescimab in Nonhematologic neoplasms, sponsored by Akeso, Inc.. Started Apr 2023; status: active.
02
Drugs
ambuzutinibivonescimab
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20230347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230347.